Latest News

The Role of Orexin Receptor 2 Agonists in Sleep and Narcolepsy Type 1

February 15th 2024

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Amanda J. Calhoun, MD, MPH
New Conference Series Focuses on Improving Mental Health Care for Black Youth

February 12th 2024

Frank A Clark, MD
Frank Clark, MD: The First Black President of The Greenville County Medical Society

February 1st 2024

“Freudian thought has massively influenced not only modern understandings of mind and therapeutic treatment, but also modernism and many distinct visions of politics.”
In Conversation With a Sigourney Award Winner: The Intersection of History, Humanities, and Psychoanalytic Thought

January 15th 2024

nasal spray
New Data on Esketamine Nasal Spray as Treatment for Adolescents Contemplating Suicide

December 12th 2023

More News

© 2024 MJH Life Sciences

All rights reserved.